• Introduction of a long-acting rhGH that reduces injection frequency while maintaining long-term growth response may improve clinical outcomes while reducing burden of daily rhGH injections Methods:
• VERTICAL was followed by the VISTA long-term safety study (NCT02068521) (Figure 2) • Inclusion criteria included growth hormone deficiency (GHD) documented by growth hormone stimulation tests, height standard deviation score [SDS] ≤ -2, IGF-I SDS ≤ -1, and delayed bone age
• Beginning the second treatment year, all subjects received 3.5 mg/kg somavaratan twice monthly, based on growth and IGF-I responses observed in Year 1 10 
Objective:
• To evaluate long-term somavaratan treatment effects through 3 years of treatment for PGHD
GP65

Conclusions:
• Phase 3 somavaratan dose selection supported by 3-year VERTICAL/VISTA study results for subjects switched to 3.5 mg/kg twice monthly
• Mean peak IGF-I SDS at 3.5 mg/kg twice monthly was in upper half of normal range over the study duration
• Mean bone age increased but did not exceed chronological age
• Normal ΔBMI SDS over 3 years of somavaratan therapy
• Improvement in height SDS continued in year 3
• Long-term IGF-I, height SDS, and HV findings comparable to ANSWER registry data for daily rhGH
• Phase 3 dose was safe and well tolerated in this study
• Frequency and severity of treatment-related AEs indicated no safety concerns 
Results:
Subject Disposition and Characteristics
• 64 subjects enrolled in VERTICAL; 60 continued in VISTA
• Baseline characteristics consistent with moderate PGHD population ( • No related SAEs; no nodule formation
• Related adverse events (AEs) were generally mild-to-moderate and transient
• Frequency of AEs declined substantially after initial 6-month exposure period
• Dose increase and new concentration did not change incidence, type, duration or severity of AE
• Subject retention was at expected rate in long-term clinical studies
Efficacy
• Increasing the somavaratan dose to 3.5 mg/kg twice monthly resulted in year 3 HV comparable to years 1 and 2 and continued improvement in Height SDS (Figure 4) • Ratio of bone age to chronological age increased from 0.80 at baseline to 0.92 in year 3, consistent with that of daily rhGH in children with GHD 11 
Mean
Safety
Figure 4. Somavaratan Effects on (A) HV and (B) Height SDS
• Somavaratan is a novel fusion protein of rhGH that has a longer half-life and duration of effect on insulin-like growth factor-I (IGF-I) responses than daily rhGH products (Figure 1 ) [7] [8] [9] • VERTICAL, a 6-month, randomized, open-label Phase 1b/2a study (NCT01718041) in 64 prepubertal children with GHD previously showed clinically meaningful improvements in 
Metabolism
• Catch-up growth accompanied by expected and normal increased weight for height
• VERTICAL and VISTA baseline body mass index (BMI) was within normal range
• Normal ΔBMI SDS over 3 years of somavaratan therapy; Δheight SDS 1.5 exceeded ΔBMI SDS 0.64 over 3 years
• No clinically significant changes in mean HbA 1c observed with increased exposure to somavaratan; mean HbA 1c was 5.2%, 5.3%, and 5.3% at months 6, 18, and 30, respectively, compared with 5.2% at VISTA study entry
• No development of overt diabetes mellitus
